The Effects of Bariatric Surgeries on Glucose Metabolism
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02823665|
Recruitment Status : Recruiting
First Posted : July 6, 2016
Last Update Posted : May 18, 2018
|Condition or disease||Intervention/treatment||Phase|
|Post Bariatric Surgery Gastric Bypass Sleeve Gastrectomy Hypoglycemia After Gastric Bypass||Drug: Exendin-(9-39) Drug: Atropine||Early Phase 1|
The purpose of this study is to determine the weight-independent effects of gastric bypass surgery and sleeve gastrectomy surgery on islet cell response after meal ingestion as mediated by hormonal and neural components of the gut. It will also address the differences between the two procedures.
Such information will be critical for the development of novel approaches for treatment of diabetes as well as improvement of glycemic effects of gastric bypass and sleeve gastrectomy in patients with partial diabetes remission or relapse after complete remission.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||The Effects of Bariatric Surgeries on Glucose Metabolism|
|Study Start Date :||July 2015|
|Estimated Primary Completion Date :||July 2022|
|Estimated Study Completion Date :||July 2022|
To evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
Other Name: no other name for Exendin-(9-39)
to evaluate the effect of neural activation on insulin secretion and glucose metabolism
A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.
Other Name: Atropine sulfate
- Insulin levels measured after nutrient ingestion [ Time Frame: Each study in the protocol is conducted up to seven hours with data collected at intervals specific to the individual study procedure. ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02823665
|Contact: Marzieh Salehi, MD MSemail@example.com|
|Contact: Andrea Hansis-Diartefirstname.lastname@example.org|
|United States, Texas|
|South Texas Veterans Health Care System||Recruiting|
|San Antonio, Texas, United States, 78229|
|Contact: Andrea Hansis-Diarte 210-567-6691 email@example.com|
|Principal Investigator: Marzieh Salehi, MD|
|Principal Investigator:||Marzieh Salehi, MD, MS||The University of Texas Health Science Center at San Antonio|